NCT07451652

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Hospital Universitario Dr. Jose E. Gonzalez · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.

Conditions

• Relapsed/Refractory Diffuse Large B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Epcoritamab	Subjects will receive 2 step up doses of Epcoritamab (0.16 mg and 0.8 mg) followed by 12 mg weekly, for a total of three 21-day cycles (8 applications)
DRUG	Gemcitabine (1000 mg/m2)	Subjects will receive gemcitabine 1000 mg/m2 on days 1 and 15 of the three 21-day cycles.
DRUG	Oxaliplatin	Subjects will receive oxaliplatin 100 mg/m2 on day 1 of three 21-day cycles.

Timeline

• Start date: 2026-03-17
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2026-03-05
• Last updated: 2026-04-01

Locations

1 site across 1 country: Mexico

Regulatory

• FDA-regulated drug study